Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients

Biological Psychiatry

Volumn 45, Issue 1, 1999, Pages 68-75

  Faustman, William O ^a,b   Bardgett, Mark ^c   Faull, Kym F ^d   Pfefferbaum, Adolf ^e   Csernansky, John G ^c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SRI INTERNATIONAL   (United States)

Author keywords

Cerebrospinal fluid; Glutamate; Neurochemistry; Neurotransmitters; Schizophrenia

Indexed keywords

CHLORAL HYDRATE; GLUTAMIC ACID; HALOPERIDOL; HOMOVANILLIC ACID;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; GAS CHROMATOGRAPHY; HALLUCINATION; HUMAN; MALE; MASS SPECTROMETRY; NEUROCHEMISTRY; PRIORITY JOURNAL; RATING SCALE; SCHIZOIDISM; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; GLUTAMIC ACID; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0033045317     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00207-8     Document Type: Article

References (45)

1. Bardgett M.E., Wrona C.T., Newcomer J.W., Csernansky J.G. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmaco. 230:1993;245-250.
2. Bunney B.G., Bunney W.E. Jr, Carlsson A. Schizophrenia and glutamate. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1205-1214 Raven Press, New York.
3. Carlsson M., Carlsson A. Schizophrenia: A subcortical neurotransmitter imbalance syndrome? Schizophr Bull. 16:1990;426-432.
4. Csernansky J.G., Murphy G.M., Faustman W.O. Limbic/mesolimbic connections and the pathogenesis of schizophrenia. Biol Psychiatry. 30:1991;383-400.
5. Csernansky J.G., Newcomer J.W., Jackson K., Lombrozo L., Faull K.F., Zipursky R., et al. Effects of raclopride treatment on plasma and CSF HVA: Relationships with clinical improvement in male schizophrenics. Psychopharmacology (Berl). 116:1994;291-296.
6. Csernansky J.G., Bardgett M.E., Sheline Y.I., Morris J.C., Olney J.W. CSF excitatory amino acids and severity of illness in Alzheimer's disease. Neurology. 46:1996;1715-1720.
7. Eastwood SL, Kerwin RW, Harrison PJ (1997): Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry Berger PA 41:636-643.
8. Faull K.F., Anderson P.J., Barchas J.D., Berger P.A. Selected ion monitoring assay for biogenic amine metabolites and probenecid in human cerebrospinal fluid. J Chromatogr: Biomed Appl. 163:1979;337-349.
9. Faustman WO, Overall JE (in press): The Brief Psychiatric Rating Scale. In: Maruish M, editor.The Use of Psychological Testing for Treatment Planning and Outcome Assessment, 2nd ed. Hillsdale, NJ: Lawrence Earlbaum.
10. Fitzgerald L.W., Deutch A.Y., Gasic G., Heinemann S.F., Nestler E.J. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci. 15:1995;2453-2461.
11. Gattaz W.F., Gattaz D., Beckmann H. Glutamate in schizophrenics and healthy controls. Arch Psychiatry Neurol Sci. 231:1982;221-225.
12. Goff D.C., Wine L. Glutamate in schizophrenia: Clinical and research implications. Schizophr Res. 27:1997;157-168.
13. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience. 41:1991;1-24.
14. Harrison P.J., McLaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452.
15. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 169:1996;610-617.
16. Ishimaru M., Kurumaji A., Toru M. Increases in styychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenis: Evidence for glutamate hypothesis. Biol Psychiatry. 35:1994;84-95.
17. Kahn R.S., Davis K.L. New developments in dopamine and schizophrenia. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1193-1203 Raven Press, New York.
18. Kelley A.E., Domesick V.B. The distribution of the projection from the hippocampal formation to the nucleus accumbens in the rat: An anterograde- and retrograde-horseradish peroxidase study. Neuroscience. 7:1982;2321-2335.
19. Kerwin R., Patel S., Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience. 39:1990;25-32.
20. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 20:1980;379-382.
21. Koob G.F., Roberts A.J., Schulteis G., Parsons L.H., Heyser C.J., Hyytia P., et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res. 22:1998;3-9.
22. Kornhuber J., Kim J.S., Kornhuber M.E., Kornhuber H.H. Chronic haloperidol administration enhances the gamma-aminobutyric acid level in rat striatum without altering the glutamate level. Eur Neurol. 23:1984;269-273.
23. Korpi E.A., Kaufmann A., Marnela K.-M. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res. 20:1987;337-345.
24. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 51:1994;199-214.
25. Labarca R., Silva H., Jerez S., Ruiz A., Reterias P., Ogalde C., et al. Effects of haloperidol on CSF glutamate levels in drug-naive schizophrenic patients. Schizophr Res. 16:1995;83-85.
26. Lopes da Silva F.H., Arnolds D.E.A.T., Neijt H.C. A functional link between the limbic cortex and ventral striatum: Physiology of the subiculum accumbens pathway. Exp Brain Res. 55:1984;205-214.
27. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry. 81:1959;363-369.
28. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., et al. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
29. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry. 42:1997;664-668.
30. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizoprenics. Neuropsychopharmacology. 17:1997;141-150.
31. McGale E.H.F., Pye I.F., Stonier C., Hutchinson E.C., Aber G.M. Studies of the interrelationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals. J Neurochem. 29:1977;291-297.
32. Olney J.W., Farber N.B. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology. 13:1995;335-345.
33. Oretti R.G., Spurlock G., Buckland P.R., McGuffin P. Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains. Neurosci Lett. 177:1994;39-43.
34. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Sale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull. 24:1988;97-99.
35. Perry T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett. 28:1982;81-85.
36. Pickar D., Labarca R., Doran A.R., Wolkowitz O.M., Roy A., Breier A., et al. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry. 43:1986;669-676.
37. Sesack S.R., Pickel V.M. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res. 527:1990;266-279.
38. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett. 121:1991;77-80.
39. Sherman A.D., Hegwood T.S., Baruah S., Waziri R. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol Psychiatry. 30:1991;1191-1198.
40. Simpson M.D.C., Slater P., Royston M.C., Deakin J.F. Regionally selective deficits in uptake sites for glutamate and gamma-aninobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res. 42:1992;273-282.
41. Totterdell S., Smith A.D. Convergence of hippocampal and dopaminergic input onto identified neurons in the nucleus accumbens of the rat. J Chem Neuroanat. 2:1989;285-298.
42. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 52:1995;829-836.
43. Walaas I., Fonnum F. Biochemical evidence for glutamate as a transmitter in hippocampal efferents to the basal forebrain and hypothalamus in the rat brain. Neuroscience. 5:1980;1691-1698.
44. Weight F.F., Aguayo L.G., White G., Lovinger D.M., Peoples R.W. GABA- and glutamate-gated ion channels as molecular sites of alcohol and anesthetic action. Adv Biochem Psychopharmacol. 47:1992;335-347.
45. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci. 14:1994;4159-4166.